Reasons to Buy �
Understand the current clinical landscape by considering the treatment options available for each patient segment .
� Visually compare the currently approved treatments available at each line of therapy , based on the most important efficacy and safety parameters tested in clinical trials .
�
�
�
�
Assess the current late-stage pipeline , in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy .
Understand the relative strengths and weaknesses of the studies used to gather these data .
Build up a nuanced understanding of the clinical benchmarks set by these products , and consider how the current late-stage pipeline will affect these benchmarks .
Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians .
Table of Contents :
1 . Report Guidance 5 2 . Adjuvant Immunotherapy 6 3 . Chemotherapy 7 4 . Targeted Therapies 9 5 . Pipeline Products 10 6 . Changes to Adjuvant Immunotherapy 2016-2022 10 7 . Changes to Advanced ( Unresectable or Metastatic ) Therapies 2016-2022 11 8 . Changes to Chemotherapy 2016-2022 11 9 . Changes to Immunotherapy 2016-2022 11 10 . Changes to Targeted Therapies 2016-2022 12
See More Reports of This Category by Radiant Insights : http :// www . radiantinsights . com / catalog / pharmaceuticals-and-healthcare
Follow Us :